Patents Examined by Noble E Jarrell
  • Pharmaceutical intermediates and methods for preparing the same
    Patent number: 10906912
    Abstract: A pharmaceutical intermediate including a first indole moiety which is associated with an optionally carboxylated hexahydroazepino moiety, an optionally carboxylated azonane moiety, or a second, optionally carboxylated indole moiety, having an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl substituent pendant from a nitrogen atom of the same.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: February 2, 2021
    Assignee: King T, LLC
    Inventor: William Allen Boulanger
  • Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
    Patent number: 10906930
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: February 2, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr., Jeffrey McKenna, Stephen M. Canham, Chudi Obioma Ndubaku
  • Riluzole prodrugs and their use
    Patent number: 10905681
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: February 2, 2021
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jefferey Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119
    Patent number: 10906894
    Abstract: There are provided compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide, and benzo[d][1,3]oxathiole 3,3-dioxide, as well as uses/methods related thereto, including treatment of diseases and condition associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: February 2, 2021
    Assignee: PRAMANA PHARMACEUTICALS INC.
    Inventors: Tarek Suhayl Mansour, Mikhail Chafeev, Mikhail Yudin, Yury Gezentsvey, Aleksandr Nikitin
  • Positive allosteric modulators of the muscarinic acetylcholine receptor M1
    Patent number: 10899759
    Abstract: Described are positive allosteric modulators of muscarinic acetylcholine receptor M1(mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: January 26, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Katrina A. Bollinger, Darren W. Engers, Anna L. Blobaum, Julie L. Engers, Jerri M. Rook
  • Compositions and methods of making metal-organic frameworks with redox-active centers
    Patent number: 10903019
    Abstract: Embodiments of the present disclosure describe an electrode material comprising a metal ion cluster and an organic linker with a redox-active center associated with the metal ion cluster sufficient to form a metal-organic framework. Embodiments of the present disclosure further describe a method of forming an electrode material comprising contacting a metal ion cluster with an organic linker including a redox-active center sufficient to form a metal-organic framework. Embodiments of the present disclosure also describe a metal-organic framework composition comprising a metal ion cluster and an organic linker with a redox-active center associated with the metal ion cluster.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: January 26, 2021
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Arijit Mallick, Bilal Ahmed, Osama Shekhah, Husam N. Alshareef, Mohamed Eddaoudi
  • Tetradentate platinum (II) complexes cyclometalated with functionalized phenyl carbene ligands and their analogues
    Patent number: 10886478
    Abstract: Tetradentate platinum complexes of Formulas I and II suitable for phosphorescent or delayed fluorescent and phosphorescent emitters in display and lighting applications.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: January 5, 2021
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jian Li, Zhi-Qiang Zhu
  • Alpha-amino pateamine A derivatives and methods for treating chronic lymphocytic leukemia
    Patent number: 10870662
    Abstract: Pateamine A derivatives and pharmaceutical compositions that include the derivatives. The pateamine A derivatives are ?-amino pateamine A derivatives that lack the C5-methyl group of pateamine A.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: December 22, 2020
    Assignee: The Texas A&M University System
    Inventors: Daniel Romo, Ken Hull, Mingzhao Zhu, Omar Robles
  • Synthesis of NIR fluorescent probe
    Patent number: 10870649
    Abstract: The application relates to a process for the synthesis of a Near Infra-Red (NIR) fluorescent probe which is a cRGD-Cy5.5 conjugate of formula (I) known as DA364 comprising an aza-bicycloalkane based cyclic peptide labelled with a Cy5.5 dye moiety and used in the guided surgery of tumors and pathologic regions.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: December 22, 2020
    Assignee: BRACCO IMAGING SPA
    Inventors: Luciano Lattuada, Federica Buonsanti, Federico Crivellin, Fulvio Ferretti, Federico Maisano, Laura Orio, Lorena Pizzuto
  • Organic compound and photoelectric conversion element
    Patent number: 10868260
    Abstract: Provided is an organic compound represented by the general formula [1]: in the formula [1], R1 to R18 each represent a hydrogen atom, an alkyl group having 1 or more and 8 or less carbon atoms, an aromatic hydrocarbon group having 6 or more and 18 or less carbon atoms, or an aromatic heterocyclic group having 3 or more and 15 or less carbon atoms, and may be identical to or different from each other, and the plurality of R17's or the plurality of R18's may be identical to or different from each other, and the R1 to the R18 may each further have a substituent selected from a halogen atom and an alkyl group having 1 or more and 8 or less carbon atoms, and n represents an integer of 1 or more and 3 or less.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: December 15, 2020
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Naoki Yamada, Masumi Itabashi, Hironobu Iwawaki, Jun Kamatani, Hiroki Ohrui, Yosuke Nishide, Hirokazu Miyashita
  • Method for synthesizing organic metal complex and organic electroluminescent element using compound synthesized by said synthesis method
    Patent number: 10862053
    Abstract: A method for synthesizing an organic metal complex having a substituent capable of coordinating to a central metal ion includes replacing substituents RX and RX? in an organic metal complex having a structure represented by general formula (2) with substituents RB and RB? in an organic metal complex having a structure represented by general formula (1), respectively:
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: December 8, 2020
    Assignee: KONICA MINOLTA, INC.
    Inventors: Motoaki Sugino, Hiroshi Kita
  • Multicyclic compounds and uses thereof
    Patent number: 10858347
    Abstract: The present invention relates to multicyclic compounds containing a urea or a guanidine moiety, or pharmaceutically acceptable salts or compositions thereof represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: December 8, 2020
    Assignee: Karyopharm Therapeutics Inc.
    Inventor: Erkan Baloglu
  • Matrix metalloproteinase (MMP) inhibitors and methods of use thereof
    Patent number: 10851089
    Abstract: Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: December 1, 2020
    Assignee: Foresee Pharmaceuticals Co., Ltd.
    Inventors: Wenjin Yang, Kai-Wei Chang, Suying Liu, Cheng-Han Tsai
  • Pyridine dicarboxamide derivatives as bromodomain inhibitors
    Patent number: 10844015
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: November 24, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Etienne Levernier, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Compounds for pain treatment, compositions comprising same, and methods of using same
    Patent number: 10844054
    Abstract: The invention relates to compounds of formula (I), compositions containing the same, and methods for treating and/or diminishing pain in a subject. The compounds of formula (I) are effective for treating opioid-induced tachyphylaxis and opioid-induced hyperalgesia.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: November 24, 2020
    Assignee: CerSci Therapeutics, Inc.
    Inventors: Scott L. Dax, Pasquale N. Confalone
  • Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof
    Patent number: 10844062
    Abstract: The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: November 24, 2020
    Assignees: Incheon University Industry Academic Cooperation Foundation, Samjin Pharmaceutical Co., Ltd., Bamichem Co., Ltd.
    Inventors: Eui Hwan Cho, Hee Jong Shin, Min Hyo Ki, Ho Seok Kwon, Jae Woong Lee, Jeong Ho Joo, Keun Kuk Lee, Jong Min Kim, Yong Bin Park, Sung Hyun Kang, Hyoung Min Cho, Hyun Tae Kim, Soon Kil Ahn, Sung Pyo Hong, Sung Hye Kim
  • 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
    Patent number: 10844066
    Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 24, 2020
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Thomas Schwarz, Ningshu Liu, Oliver Politz, Michael Gerisch, Dieter Lang
  • Aurora kinase inhibitors for inhibiting mitotic progression
    Patent number: 10836766
    Abstract: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: November 17, 2020
    Assignee: MILLENIUM PHARMACEUTICALS, INC.
    Inventors: Christopher F. Claiborne, Todd B. Sells, Stephen G. Stroud
  • Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses
    Patent number: 10836770
    Abstract: Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of formula I are useful for the treatment of inflammatory or autoimmune diseases.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: November 17, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Steven H. Spergel, Michael E. Mertzman
  • 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis
    Patent number: 10829478
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: November 10, 2020
    Assignee: GALAPAGOS NV
    Inventors: Frédéric Gilbert Labéguère, Rama Heng, Frédéric André De Ceuninck, Luke Jonathan Alvey, David Amantini, Franck Laurent Brebion, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin